Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660387 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Phase 3 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT00660387 is a Phase 3 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 35 participants.
The verdict
NCT00660387, a Phase 3 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
Interventions
- DRUG Placebo Gel
- DEVICE CADD-Legacy® 1400 ambulatory infusion pump
- DRUG Levodopa carbidopa intestinal gel (LCIG)
- DRUG Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
- DRUG Placebo (PBO) oral capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660387
The ClinicalTrials.gov registry entry for NCT00660387 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo Gel is the first listed.
NCT00660387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660387 about?
NCT00660387 is a clinical study titled "Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects". The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
What is the current status of trial NCT00660387?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2009-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00660387?
The interventions under investigation include: Placebo Gel (DRUG), CADD-Legacy® 1400 ambulatory infusion pump (DEVICE), Levodopa carbidopa intestinal gel (LCIG) (DRUG), Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets (DRUG), Placebo (PBO) oral capsules (DRUG).
Who is sponsoring clinical trial NCT00660387?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.